NCT01618357: Pre-Operative Radiation and Veliparib for Breast Cancer

NCT01618357
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Misc Inhibitor, Radiation Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with metaplastic breast carcinomas
https://ClinicalTrials.gov/show/NCT01618357

Comments are closed.

Up ↑